SALT LAKE CITY–(BUSINESS WIRE)–iVeena Delivery Systems (iVeena), a clinical stage biopharmaceutical company with developmental products in cataract and cornea, announces the appointment of Robert Dempsey, former Group Vice President and Head of the G…
Glaukos Corporation to Release Third Quarter 2019 Financial Results after Market Close on November 6
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release thir…
3M Supports Nobel Prize Dialogue Event Focused on Health in Berlin
BERLIN–(BUSINESS WIRE)–3M will help bring the acclaimed Nobel Prize Dialogue event to Berlin for a conversation among world-leading thinkers on health.
Study: Most adults born prematurely survive without developing major comorbidities
Most people born prematurely are likely to survive into adulthood without developing major chronic diseases or conditions like asthma, hypertension, diabetes, and other illnesses, Mount Sinai researchers report in a study published today in the Journal…
Researchers receive $3.2 million NIH grant to pursue a deeper understanding of Down syndrome
Mount Sinai researchers have been awarded a $3.2 million grant from the National Institutes of Health to pursue a deeper understanding of Down syndrome, the most common genetic cause of intellectual and developmental disabilities in children and young …
VIDEO: How less aggressive treatment affects diabetic retinopathy severity scores
SAN FRANCISCO — At the American Academy of Ophthalmology meeting, Roger A. Goldberg, MD, discusses the findings from a study regarding the effect of less aggressive treatment on diabetic retinopathy severity scores.